Latest progressive multifocal leukoencephalopathy Stories

May 11, 2013 Grand Hotel Bristol, Stresa, Italy ATLANTA, April 25, 2013 /PRNewswire/ -- Inhibikase Therapeutics, Inc., an emerging leader in infectious disease, announced today that it will update the scientific and medical community on the development program for IkT-001Pro. IkT-001Pro, a host-directed tyrosine kinase inhibitor in an extended release formulation, is intended to clear JC polyomavirus (JCV) infection, the causative agent of Progressive Multifocal...

The drug natalizumab is effective for treating multiple sclerosis (MS), but it increases the risk of a rare but potentially fatal brain infection called progressive multifocal leukoencephalopathy (PML). A study released today that will be presented at the American Academy of Neurology's 65th Annual Meeting in San Diego, March 16 to 23, 2013, suggests that early detection of PML may help improve survival and disability levels. The study examined 319 people with MS who were treated with...

SAN DIEGO, March 10, 2013 /PRNewswire-USNewswire/ -- The drug natalizumab is effective for treating multiple sclerosis (MS), but it increases the risk of a rare but potentially fatal brain infection called progressive multifocal leukoencephalopathy (PML). A study released today that will be presented at the American Academy of Neurology's 65th Annual Meeting in San Diego, March 16 to 23, 2013, suggests that early detection of PML may help improve survival and disability levels. The...

TORONTO, May 23, 2012 /CNW/ - Today Biogen Idec announced that Health Canada has approved a product monograph change for TYSABRI® that will help enable individual benefit risk assessment for patients with multiple sclerosis (MS). The new label identifies anti-JC virus (JCV) antibody status as a risk factor for developing an uncommon, but serious, brain infection known as progressive multifocal leukoencephalopathy (PML). This marks the third risk factor identified to help...

COLUMBIA, Md., March 14, 2012 /PRNewswire/ -- The PML Consortium, an association of pharmaceutical and biotechnology companies, has recently selected the Labmatrix and Qiagram software environments from BioFortis to share and manage data relating to biospecimens in a collaborative effort to study a serious adverse event. Progressive multifocal leukoencephalopathy (PML) is an often-fatal disease caused by the JC virus in immunocompromised patients. PML has been identified as a known...

MADISON, N.J., Jan. 20, 2012 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that the U.S. Food and Drug Administration (FDA) has granted a de novo classification petition to its STRATIFY JCV(TM) Antibody ELISA testing service. STRATIFY JCV is the first blood test to be FDA market authorized for the qualitative detection of antibodies to the polyomavirus JC virus (JCV) for stratifying risk...

SILVER SPRING, Md., Jan. 20, 2012 /PRNewswire-USNewswire/ -- Today, the U.S. Food and Drug Administration allowed marketing of the first test to help determine the risk for a rare brain infection called progressive multifocal leukoencephalopathy (PML) in people using the drug Tysabri (natalizumab) to treat multiple sclerosis (MS) or Crohn's disease (CD). (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) The Stratify JCV Antibody ELISA test, when used with other clinical data from...

ProgressiveMultifocalLeukoencephalopathy.org aims to assist individuals in learning about PML. (PRWEB) November 28, 2011 Flood Law Group, LLP, a litigation firm, is announcing the launch of the new website, ProgressiveMultifocalLeukoencephalopathy.org, designed to assist individuals in learning about progressive multifocal leukoencephalopathy (PML), a disorder that harms the tissue surrounding the nerves in the brain and spinal cord. According to Flood Law Group, LLP, people who are...

Taking the new generation anti-inflammatory drug natalizumab for two years lowers the number of remitting multiple sclerosis patients who experience relapses and progression of disability. This is the main finding of a systematic review published in the latest edition of The Cochrane Library. Multiple sclerosis (MS) is a disease that damages a person's nervous system. The symptoms vary considerably from person to person, but many have a form of the disease in which they feel healthy for a...

ATLANTA, Aug. 16, 2011 /PRNewswire/ -- Inhibikase Therapeutics, Inc., an emerging leader in infectious disease, announced today that it has received FDA clearance to commence a Phase II proof-of-concept trial for its lead compound IkT-001. IkT-001, a host-directed kinase inhibitor, is intended to clear JC polyomavirus (JCV) infection, the causative agent of Progressive Multifocal Leukoencephalopathy (PML). This proof-of-concept trial will be conducted in multiple sclerosis (MS) patients...